CD274 and neoplasm: Furthermore, our results suggest that an antiangiogenic TKI, such as nintedanib, or MTD chemotherapy (using paclitaxel) may both improve the antitumor efficacy of PD-L1 antibody (and/or vice versa) when administered as a combination, in the primary tumor treatment setting, whereas, interestingly, the triple combination appears to be more effective when treating advanced metastatic TNBC compared to the standard MTD paclitaxel treatment.